Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2019
Reporting Period: Event date December 17, 2019; Expected closing December 19, 2019.
Business Context: The Company, a Delaware corporation focused on exosome technologies, announced the pricing of a capital raising transaction involving common stock, warrants, and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure:
- 531,173 shares of Common Stock at $1.226 per share (plus associated warrants).
- Pre-Funded Warrants to purchase 3,608,304 shares at $1.225 per warrant (plus associated warrants).
- Common Warrants issued to purchase up to 4,139,477 shares total.
- Warrant Terms:
- Common Warrants: Exercise price of $1.10 per share; exercisable immediately; expire five years from issuance; subject to cashless exercise at expiration.
- Pre-Funded Warrants: Exercise price of $0.001 per share; immediately exercisable.
- Net Proceeds: Approximately $4.4 million (after placement agent fees and estimated offering expenses).
- Use of Proceeds: Funding research and development of exosome technologies, supporting an IND filing, manufacturing costs, hiring personnel, business development, and general corporate purposes.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with a single institutional investor. Key covenants include:
- Lock-up Period: Prohibition on issuing Common Stock or convertible securities for 90 days post-closing.
- Variable Rate Transactions: Prohibition on entering into variable rate transactions for 12 months post-closing.
- Ownership Limitations: Holders cannot exercise warrants if it results in beneficial ownership exceeding 4.99% (or up to 9.99% at election), subject to a 61-day notice period for increases.
- Director Participation: Certain directors purchased shares and warrants on substantially the same terms as the institutional investor.
Guidance, Outlook, and Risks
Outlook: The Company intends to utilize the proceeds to advance its exosome technology pipeline, specifically to support the filing of an Investigational New Drug (IND) application in a designated indication and to continue development of CAP-1002.
Risks and Contingencies:
- Closing is subject to satisfaction or waiver of customary conditions.
- Dilution risk due to the issuance of shares and warrants.
- Restrictions on future capital raising activities due to the 90-day lock-up and 12-month variable rate transaction prohibition.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (expected ~$4.4 million).
- Confirm the specific indication designated for the upcoming IND filing.
- Monitor compliance with the 90-day lock-up period regarding future equity issuances.
- Review the impact of the 4.99%/9.99% beneficial ownership limits on potential future warrant exercises by major holders.
- Check for any subsequent filings regarding the status of the CAP-1002 development program.